Bravecto Quantum becomes first FDA approved drug to protect dogs against fleas and ticks for 8 to 12 months.
Nicholas Jacobus
Advertisement
Nicholas Jacobus is a content associate for Pharmaceutical Executive and can be reached at njacobus@mjhlifesciences.com.
Articles by Nicholas Jacobus
rs6190 helps men build muscle mass and reduce diabetes risk, but increases cholesterol levels and elevates the risk of clogged arteries and heart disease in women.
The company will continue to experiment with microgravity-derived experiments.
TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.
The drug is currently in Phase 1 clinical trials for gastric cancer treatments.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
3
The Battle to Own the GLP-1 Patient Journey
4
Novo Announces Drug Discovery Collaboration with Anthropic
5